Company Benitec Biopharma Inc. Deutsche Boerse AG
Equities
BJ9
US08205P2092
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 EUR | -2.70% | -.--% | -.--% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jerel Banks
CEO | Chief Executive Officer | 49 | 30/09/16 |
Peter Roelvink
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/15 |
Megan Boston
CMP | Compliance Officer | 52 | 31/07/16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
J. Buchi
BRD | Director/Board Member | 69 | 31/03/13 |
Edward Smith
BRD | Director/Board Member | 53 | 13/04/20 |
Peter Francis
BRD | Director/Board Member | 68 | 31/01/06 |
Jerel Banks
CEO | Chief Executive Officer | 49 | 30/09/16 |
Megan Boston
CMP | Compliance Officer | 52 | 31/07/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,367,485 | 8,497,929 ( 90.72 %) | 0 | 90.72 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- BNTC Stock
- BJ9 Stock
- Company Benitec Biopharma Inc.